Table 4.
Univariate Cox Proportional Hazards Analysis of Progression-Free and Overall Survival
| Covariates | mPFS, months | HR (95% CI) | Pa | mOS, months | HR (95% CI) | Pa |
|---|---|---|---|---|---|---|
| Age | ||||||
| Continuous | — | 1.006 (0.986, 1.026) | .593 | — | 0.992 (0.972, 1.01) | .480 |
| Gender | ||||||
| Male | 13.0 | 1 | — | 27.7 | 1 | — |
| Female | 7.63 | 1.63 (1.09, 2.46) | .018 | 19.6 | 1.26 (0.799, 1.97) | .324 |
| Prior therapy | ||||||
| Cytokine-refractory | 13.0 | 1 | — | 30.0 | 1 | — |
| Sorafenib-refractory | 7.63 | 1.55 (1.02, 2.34) | .038 | 15.8 | 2.15 (1.39, 3.34) | <.001 |
| ECOG PS | ||||||
| 0 | 13.7 | 1 | — | 41.6 | 1 | — |
| 1 | 7.13 | 2.17 (1.46, 3.23) | <.001 | 10.7 | 3.63 (2.40, 5.48) | <.001 |
| Hemoglobin (g/dL) | ||||||
| ≤ 13 for male, ≤ 11.5 for female | 7.69 | 1 | — | 15.9 | 1 | — |
| >13 for male, >11.5 for female | 14.6 | 0.537 (0.364, 0.792) | .001 | 43.3 | 0.282 (0.179, 0.443) | <.001 |
| Corrected serum calcium, mg/dL | ||||||
| <10 | 11.1 | 1 | — | 27.7 | 1 | — |
| ≥10 | 8.38 | 1.21 (0.688, 2.13) | .507 | 16.4 | 1.74 (1.03, 2.96) | .038 |
| AUC, hxng/mL | ||||||
| Continuousb | — | 0.871 (0.801, 0.947) | .001 | — | 0.810 (0.733, 0.897) | <.001 |
| <300 | 7.4 | 1 | — | 15.8 | 1 | — |
| ≥300 | 13.8 | 0.558 (0.379 0.823) | .003 | 37.4 | 0.489 (0.324, 0.738) | <.001 |
| dBP, mm Hg | ||||||
| Continuousc | — | 0.604 (0.487, 0.750) | <.001 | — | 0.652 (0.524, 0.811) | <.001 |
| <90 | 7.86 | 1 | — | 18.5 | 1 | — |
| ≥90 | 14.6 | 0.590 (0.402, 0.866) | .006 | 29.5 | 0.622 (0.411, 0.942) | .024 |
AUC, area under the plasma concentration–time curve; CI, confidence interval; dBP, diastolic blood pressure; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; mOS, median overall survival; mPFS, median progression-free survival.
a
Based on log-rank (score) test at significance level of P = .1 for inclusion in multivariate model.
b
Hazard ratio per 100 hxng/mL increase of AUC.
c
Hazard ratio per 10 mm Hg increase of dBP.